Sinobiopharma seeks Chinese patent to develop anti-hypertension drugs

Sinobiopharma is reportedly the world’s first manufacturer and marketer of Perindopril in capsule form. The company’s patent application covers the method of preparation and stability for new drug compounds containing Perindopril.

Perindopril, used alone or in combination with other medications to treat high blood pressure, is the latest generation of a class of medications called angiotensin-converting enzyme inhibitors. It supports circulation by preventing the production of chemicals that occur naturally in the body but constrict blood vessels, the company said.

Xuejun Chen, vice president of Sinobiopharma, said: “As China’s first maker of the next generation of Perindopril, Sinobiopharma comes to market with significant competitive advantages including lower active pharmaceutical ingredient costs, an easier-to-swallow formula, greater efficacy and reduced side effects compared to earlier versions of the drug. We look forward to launching the next generation of Perindopril compounds, following confirmation of the standardization of usage, later in 2009.”